Free Trial

LivaNova (LIVN) Stock Forecast & Price Target

LivaNova logo
$34.35 -1.05 (-2.97%)
As of 02:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LivaNova - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
6

Based on 8 Wall Street analysts who have issued ratings for LivaNova in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 2 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for LIVN.

Consensus Price Target

$61.17
78.07% Upside
According to the 8 analysts' twelve-month price targets for LivaNova, the average price target is $61.17. The highest price target for LIVN is $72.00, while the lowest price target for LIVN is $55.00. The average price target represents a forecasted upside of 78.07% from the current price of $34.35.
Get the Latest News and Ratings for LIVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for LivaNova and its competitors.

Sign Up

LIVN Analyst Ratings Over Time

TypeCurrent Forecast
4/8/24 to 4/8/25
1 Month Ago
3/9/24 to 3/9/25
3 Months Ago
1/9/24 to 1/8/25
1 Year Ago
4/9/23 to 4/8/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$61.17$61.17$69.17$64.40
Forecasted Upside78.07% Upside56.16% Upside43.98% Upside17.73% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Hold
Remove Ads

LIVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LIVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

LivaNova Stock vs. The Competition

TypeLivaNovaMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside78.28% Upside19,376.68% Upside33.58% Upside
News Sentiment Rating
Positive News

See Recent LIVN News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/17/2025Needham & Company LLC
2 of 5 stars
Mike Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$64.00 ➝ $64.00+63.10%
3/7/2025Barclays
3 of 5 stars
Matt Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$58.00 ➝ $56.00+40.03%
3/3/2025The Goldman Sachs Group
3 of 5 stars
D. Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$64.00 ➝ $55.00+32.74%
2/26/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$70.00 ➝ $60.00+45.77%
2/26/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rick Wise
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$72.00 ➝ $60.00+43.88%
2/26/2025Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Peer Perform
10/31/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$66.00 ➝ $72.00+40.24%
9/17/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
9/6/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$52.00-4.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:34 PM ET.


LIVN Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for LivaNova is $61.17, with a high forecast of $72.00 and a low forecast of $55.00.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LIVN shares.

According to analysts, LivaNova's stock has a predicted upside of 78.07% based on their 12-month stock forecasts.

Over the previous 90 days, LivaNova's stock had 1 downgrade by analysts.

LivaNova has been rated by research analysts at Barclays, Mizuho, Needham & Company LLC, Stifel Nicolaus, The Goldman Sachs Group, and Wolfe Research in the past 90 days.

Analysts like LivaNova more than other "medical" companies. The consensus rating score for LivaNova is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how LIVN compares to other companies.


This page (NASDAQ:LIVN) was last updated on 4/8/2025 by MarketBeat.com Staff
From Our Partners